Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name file name title title
tabling member	label

Search

516972

	registered interest
	date	03/05/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Olympic Games: Brazil
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government, further to the Written Answers by Lord Prior of Brampton on 11 and 12 February (HL5764 and HL5766) and by Baroness Neville-Rolfe on 11 February (HL5765), and in the light of current information about the increased extent of dangers from the Zika virus affecting up to 20 per cent of all births, whether they intend to issue further advice about, or to reconsider, in consultation with other European governments, the long-term implications of participating in or attending the 2016 Olympic Games in Brazil.
	tabling member printed	Lord Maginnis of Drumglass
	uin	HL8128
	answer	answer is ministerial correction date of answer 11/05/2016 answer text <p>The British Olympic Association (BOA) and British Paralympic Association (BPA) have prepared guidance to consider the health risks, including those posed by Zika, for British athletes and staff travelling to Brazil for the Olympics.</p><p> </p><p>The Department of Health has convened an Olympics health advisory group on behalf of the Department for Culture, Media and Sport to focus on Zika and to support the BOA and BPA to ensure that they can continue to provide the best possible information and advice.</p><p> </p><p>The group will be chaired by the Department’s Chief Scientific Advisor, Professor Chris Whitty, and will bring together experts from the BOA and BPA as well as the London School of Hygiene and Tropical Medicine, University of Liverpool, University of Nottingham, the Royal Free London, Public Health England and across Government.</p><p> </p><p>Revisions of existing guidance or specific further advice will be published if it is deemed necessary.</p><p> </p><p>In the meantime, Public Health England and the National Travel Health Network and Centre (NaTHNaC) have developed and issued more general travel advice online to health professionals that is suitable for people travelling to Zika-affected countries, including pregnant women. A copy of the online advice is attached.</p><p> </p><p>This includes a list of countries where Zika virus transmission is occurring, advice around bite avoidance measures and what and who to speak to if those travelling have concerns. PHE and NaTHNaC continue to monitor the situation very closely and update advice as needed.</p> answering member printed Lord Prior of Brampton question first answered 11/05/2016 16:20:48 answering member 127 label Biography information for Lord Prior of Brampton attachment 1 file name zika-virus-update-and-advice-for-travellers-including-pregnant-women.pdf title Zika Virus travel advice
	tabling member	648 label Biography information for Lord Maginnis of Drumglass

92992

	registered interest
	date	13/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what guidance his Department provides to clinical commissioning groups about commissioning services on treatments from hospitals (a) in Scotland and (b) outside their own area.
	tabling member constituency	Berwick-upon-Tweed
	tabling member printed	Sir Alan Beith
	uin	210196
	answer	answer is ministerial correction date of answer 16/10/2014 answer text <p>Clinical commissioning groups’ (CCGs) commissioning responsibilities are set out in the NHS Act 2006, The National Health Service Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012 (SI 2012/2996) and The National Health Service (Clinical Commissioning Groups— Disapplication of Responsibility) Regulations 2013 (SI 2013/350), as amended.</p><p> </p><p> </p><p> </p><p>NHS England have published the document ‘Who Pays? Determining responsibility for payments to providers’ which provides guidance for CCGs on commissioning services from hospitals in Scotland and outside their own area.</p><p> </p><p> </p><p> </p><p>A copy is attached.</p><p> </p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 16/10/2014 15:10:39 answering member 1439 label Biography information for Norman Lamb attachment 1 file name who-pays.pdf title Who Pays? NHS England August 2013
	tabling member	513 label Biography information for Lord Beith

386906

	registered interest
	date	01/07/2015
	answering body	Department for Business, Innovation and Skills
	answering dept id	26
	answering dept short name	Business, Innovation and Skills
	answering dept sort name	Business, Innovation and Skills
	hansard heading	Small Businesses: Audit
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what data they used to estimate the savings made from enabling small businesses to decide whether their accounts need to be audited.
	tabling member printed	Lord Mendelsohn
	uin	HL1015
	answer	answer is ministerial correction date of answer 14/07/2015 answer text <p>Data on company size and audit fees was sourced from the “FAME” database, Bureau van Dijk. The data was used for both of the final impact assessments approved by the Regulatory Policy Committee in the last Parliament on changes to the law to enable more companies to decide whether or not their accounts need to be audited.</p><p> </p><p>The impact assessment on the audit changes (including for small businesses) in the Companies and Limited Liability Partnerships (Accounts and Audit Exemptions and Change of Accounting Framework) Regulations 2012 is available at: <a href="http://www.legislation.gov.uk/uksi/2012/2301/impacts/2014/286" target="_blank">http://www.legislation.gov.uk/uksi/2012/2301/impacts/2014/286</a></p><p> </p><p>The impact assessment on all the changes in the Companies, Partnerships and Groups (Accounts and Reports) Regulations 2015 is available at: <a href="http://www.legislation.gov.uk/uksi/2015/980/impacts/2014/424" target="_blank">http://www.legislation.gov.uk/uksi/2015/980/impacts/2014/424</a></p><p> </p><p> </p><p> </p> answering member printed Baroness Neville-Rolfe attachment 1 file name ukia_20140286_en.pdf title Audit Changes 2 file name ukia_20140424_en.pdf title Changes in the Companies. Partnerships and groups question first answered 14/07/2015 11:25:06 answering member 4284 label Biography information for Baroness Neville-Rolfe
	tabling member	4286 label Biography information for Lord Mendelsohn

450641

	registered interest
	date	04/02/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Accident and Emergency Departments
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what steps they are taking to develop the model of co-location of urgent and emergency primary care service with accident and emergency departments.
	tabling member printed	Baroness Masham of Ilton
	uin	HL5942
	answer	answer is ministerial correction date of answer 11/02/2016 answer text <p>In August 2015, NHS England published <em>Safer, faster, better: good practice in delivering urgent and emergency care. </em>A copy is attached. This provides guidance to help frontline providers and commissioners re-design urgent and emergency care services, including considering locating urgent care centres in emergency departments.</p><p><em>Safer, faster, better</em> notes that urgent care centres co-located with emergency departments provide an opportunity to stream patients with less serious illnesses and injuries to a service that is resourced to meet their needs, while reducing crowding in emergency departments. It also sets out that to preserve flow, urgent care centre staff and cubicles must wherever possible be entirely separated from the majors/admission stream and that where urgent care centres are co-located with emergency departments, there must be appropriate integration, with shared governance arrangements and clearly defined protocols for the two-way transfer of patients.</p> answering member printed Lord Prior of Brampton question first answered 11/02/2016 12:53:09 answering member 127 label Biography information for Lord Prior of Brampton attachment 1 file name trans-uec - HL5942.pdf title Safer, Faster, Better
	tabling member	1850 label Biography information for Baroness Masham of Ilton

447470

	registered interest
	date	25/01/2016
	answering body	Department for Culture, Media and Sport
	answering dept id	10
	answering dept short name	Culture, Media and Sport
	answering dept sort name	Culture, Media and Sport
	hansard heading	Employment: Electronic Surveillance
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what assessment they have made of the impact of the European Court of Human Rights ruling on 12 January in <i>Barbulescu v Romania</i> on an employer's right to access an employee's private emails in the UK.
	tabling member printed	Lord Chadlington
	uin	HL5372
	answer	answer is ministerial correction date of answer 09/02/2016 answer text <p>The Government has made no assessment of the judgment The case raises the important question of whether the Applicant had a reasonable expectation that his communications would not be monitored; and could reasonably expect privacy when communicating from the Yahoo Messenger account that he had registered at his employer's request, and where there was a strict company policy prohibiting use of work systems for personal purposes. The Applicant alleged interference with his article 8 rights and that the interference was not foreseeable or proportionate. But the Court held that there was nothing to indicate that the domestic authorities failed to strike a fair balance between the applicant’s right to respect for his private life under Article 8 and his employer’s interests, and that there had been no violation of Article 8 of the Convention.</p><p> </p><p>The attached ICO's employment practices code sets out guidance in relation to workplace monitoring. The code is already clear that employers should have policies in place explaining how they expect their IT systems to be used, including setting out the extent to which, if any, the IT system can be used for personal use. Even where no such policy is in place, it is reasonable in certain circumstances for employers to monitor an employee’s use of the IT systems to ensure compliance with any policy or to ensure that employees are not abusing the use of the system. Such monitoring may include accessing non-work communications but this should only be done in exceptional circumstances.</p> answering member printed Baroness Neville-Rolfe question first answered 09/02/2016 14:25:09 answering member 4284 label Biography information for Baroness Neville-Rolfe attachment 1 file name the_employment_practices_code.pdf title ICO Employment Code
	tabling member	3318 label Biography information for Lord Chadlington

421268

	registered interest
	date	14/10/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Hypothyroidism
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what steps they have taken to help patients with undiagnosed hypothyroidism who present clinical signs and symptoms of that condition, but are refused any treatment as their blood test results remain normal.
	tabling member printed	Lord Pendry
	uin	HL2639
	answer	answer is ministerial correction date of answer 27/10/2015 answer text <p>A blood test measuring hormone levels is the only accurate way to find out if there is a thyroid problem.</p><br /><p>Best practice on the identification and management of hypothyroidism has been set out by the Royal College of Physicians (RCP) in its guidance, <em>The Diagnosis and Management of Primary Hypothyroidism</em>, first published in 2008. The guidance, which is attached, was developed on behalf of key organisations, including the British Thyroid Association (BTA), the British Thyroid Foundation (BTF) and the Society for Endocrinology (SOE), and is endorsed by the Royal College of General Practitioners. A copy of the UK Guidelines is attached.</p><br /><p>The RCP guidance sets out that the only validated method of testing thyroid function is through a blood sample, which must include measurement of the levels of thyroid‐stimulating hormone (TSH) and free thyroxine (FT4) in serum, as recommended in the <em>UK Guidelines for the Use of Thyroid Function Tests</em> published by the BTA.</p><br /><p>The RCP guidelines set out that overwhelming evidence supports the use of thyroxine hormone replacement (T4 or tetra-iodothyronine) alone in the treatment of hypothyroidism, with this usually being prescribed as levothyroxine. However, this does not prevent clinicians considering other forms of thyroid hormone replacement if appropriate.</p><p>The guidance remains up-to-date and a statement from the BTA Executive Committee supporting the existing guidelines was published in May 2015 in <em>Clinical Endocrinology</em> and endorsed by the Association for Clinical Biochemistry and Laboratory Medicine, the BTF, the RCP and the SOE. The full statement is attached and available online at:</p><br /><p><a href="http://onlinelibrary.wiley.com/doi/10.1111/cen.12824/full" target="_blank">http://onlinelibrary.wiley.com/doi/10.1111/cen.12824/full</a></p><br /><p>Regarding international guidance and harmonisation on approaches to testing, the existing United Kingdom guidelines have now been supported by new guidance published in the United States of America which draws on the latest research and available evidence on the management of the condition. The USA guidance also includes a section on the ethics of prescribing thyroid hormone combination therapies when the potential long-term harmful effects are not known.</p> answering member printed Lord Prior of Brampton attachment 1 file name Okosieme_et_al-2015-Clinical_Endocrinology.pdf title Clinical Endocrinology paper 2 file name the-diagnosis-and-management-of-primary-hypothyroidism-revised-statement-14-june-2011_2.pdf title Royal College of Physicians guidance 3 file name TFT_guideline_final_version_July_2006.pdf title UK Guidelines Thyroid Function Tests grouped question UIN HL2640 HL2641 HL2642 question first answered 27/10/2015 17:53:42 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	457 label Biography information for Lord Pendry

421269

	registered interest
	date	14/10/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Hypothyroidism
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government whether there are any plans to amend the diagnosis of hypothyroidism, which under current guidance is based solely on a blood test.
	tabling member printed	Lord Pendry
	uin	HL2640
	answer	answer is ministerial correction date of answer 27/10/2015 answer text <p>A blood test measuring hormone levels is the only accurate way to find out if there is a thyroid problem.</p><br /><p>Best practice on the identification and management of hypothyroidism has been set out by the Royal College of Physicians (RCP) in its guidance, <em>The Diagnosis and Management of Primary Hypothyroidism</em>, first published in 2008. The guidance, which is attached, was developed on behalf of key organisations, including the British Thyroid Association (BTA), the British Thyroid Foundation (BTF) and the Society for Endocrinology (SOE), and is endorsed by the Royal College of General Practitioners. A copy of the UK Guidelines is attached.</p><br /><p>The RCP guidance sets out that the only validated method of testing thyroid function is through a blood sample, which must include measurement of the levels of thyroid‐stimulating hormone (TSH) and free thyroxine (FT4) in serum, as recommended in the <em>UK Guidelines for the Use of Thyroid Function Tests</em> published by the BTA.</p><br /><p>The RCP guidelines set out that overwhelming evidence supports the use of thyroxine hormone replacement (T4 or tetra-iodothyronine) alone in the treatment of hypothyroidism, with this usually being prescribed as levothyroxine. However, this does not prevent clinicians considering other forms of thyroid hormone replacement if appropriate.</p><p>The guidance remains up-to-date and a statement from the BTA Executive Committee supporting the existing guidelines was published in May 2015 in <em>Clinical Endocrinology</em> and endorsed by the Association for Clinical Biochemistry and Laboratory Medicine, the BTF, the RCP and the SOE. The full statement is attached and available online at:</p><br /><p><a href="http://onlinelibrary.wiley.com/doi/10.1111/cen.12824/full" target="_blank">http://onlinelibrary.wiley.com/doi/10.1111/cen.12824/full</a></p><br /><p>Regarding international guidance and harmonisation on approaches to testing, the existing United Kingdom guidelines have now been supported by new guidance published in the United States of America which draws on the latest research and available evidence on the management of the condition. The USA guidance also includes a section on the ethics of prescribing thyroid hormone combination therapies when the potential long-term harmful effects are not known.</p> answering member printed Lord Prior of Brampton attachment 1 file name Okosieme_et_al-2015-Clinical_Endocrinology.pdf title Clinical Endocrinology paper 2 file name the-diagnosis-and-management-of-primary-hypothyroidism-revised-statement-14-june-2011_2.pdf title Royal College of Physicians guidance 3 file name TFT_guideline_final_version_July_2006.pdf title UK Guidelines Thyroid Function Tests grouped question UIN HL2639 HL2641 HL2642 question first answered 27/10/2015 17:53:42 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	457 label Biography information for Lord Pendry

421270

	registered interest
	date	14/10/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Hypothyroidism
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what progress is being made on the initiative to achieve greater harmonisation on approaches to diagnosing hypothyroidism internationally.
	tabling member printed	Lord Pendry
	uin	HL2641
	answer	answer is ministerial correction date of answer 27/10/2015 answer text <p>A blood test measuring hormone levels is the only accurate way to find out if there is a thyroid problem.</p><br /><p>Best practice on the identification and management of hypothyroidism has been set out by the Royal College of Physicians (RCP) in its guidance, <em>The Diagnosis and Management of Primary Hypothyroidism</em>, first published in 2008. The guidance, which is attached, was developed on behalf of key organisations, including the British Thyroid Association (BTA), the British Thyroid Foundation (BTF) and the Society for Endocrinology (SOE), and is endorsed by the Royal College of General Practitioners. A copy of the UK Guidelines is attached.</p><br /><p>The RCP guidance sets out that the only validated method of testing thyroid function is through a blood sample, which must include measurement of the levels of thyroid‐stimulating hormone (TSH) and free thyroxine (FT4) in serum, as recommended in the <em>UK Guidelines for the Use of Thyroid Function Tests</em> published by the BTA.</p><br /><p>The RCP guidelines set out that overwhelming evidence supports the use of thyroxine hormone replacement (T4 or tetra-iodothyronine) alone in the treatment of hypothyroidism, with this usually being prescribed as levothyroxine. However, this does not prevent clinicians considering other forms of thyroid hormone replacement if appropriate.</p><p>The guidance remains up-to-date and a statement from the BTA Executive Committee supporting the existing guidelines was published in May 2015 in <em>Clinical Endocrinology</em> and endorsed by the Association for Clinical Biochemistry and Laboratory Medicine, the BTF, the RCP and the SOE. The full statement is attached and available online at:</p><br /><p><a href="http://onlinelibrary.wiley.com/doi/10.1111/cen.12824/full" target="_blank">http://onlinelibrary.wiley.com/doi/10.1111/cen.12824/full</a></p><br /><p>Regarding international guidance and harmonisation on approaches to testing, the existing United Kingdom guidelines have now been supported by new guidance published in the United States of America which draws on the latest research and available evidence on the management of the condition. The USA guidance also includes a section on the ethics of prescribing thyroid hormone combination therapies when the potential long-term harmful effects are not known.</p> answering member printed Lord Prior of Brampton attachment 1 file name Okosieme_et_al-2015-Clinical_Endocrinology.pdf title Clinical Endocrinology paper 2 file name the-diagnosis-and-management-of-primary-hypothyroidism-revised-statement-14-june-2011_2.pdf title Royal College of Physicians guidance 3 file name TFT_guideline_final_version_July_2006.pdf title UK Guidelines Thyroid Function Tests grouped question UIN HL2639 HL2640 HL2642 question first answered 27/10/2015 17:53:43 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	457 label Biography information for Lord Pendry

421271

	registered interest
	date	14/10/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Hypothyroidism
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government whether there are any plans to amend the treatment of hypothyroidism by including thyroid hormone combination therapies other than treatment by levothyroxine in the standard of care.
	tabling member printed	Lord Pendry
	uin	HL2642
	answer	answer is ministerial correction date of answer 27/10/2015 answer text <p>A blood test measuring hormone levels is the only accurate way to find out if there is a thyroid problem.</p><br /><p>Best practice on the identification and management of hypothyroidism has been set out by the Royal College of Physicians (RCP) in its guidance, <em>The Diagnosis and Management of Primary Hypothyroidism</em>, first published in 2008. The guidance, which is attached, was developed on behalf of key organisations, including the British Thyroid Association (BTA), the British Thyroid Foundation (BTF) and the Society for Endocrinology (SOE), and is endorsed by the Royal College of General Practitioners. A copy of the UK Guidelines is attached.</p><br /><p>The RCP guidance sets out that the only validated method of testing thyroid function is through a blood sample, which must include measurement of the levels of thyroid‐stimulating hormone (TSH) and free thyroxine (FT4) in serum, as recommended in the <em>UK Guidelines for the Use of Thyroid Function Tests</em> published by the BTA.</p><br /><p>The RCP guidelines set out that overwhelming evidence supports the use of thyroxine hormone replacement (T4 or tetra-iodothyronine) alone in the treatment of hypothyroidism, with this usually being prescribed as levothyroxine. However, this does not prevent clinicians considering other forms of thyroid hormone replacement if appropriate.</p><p>The guidance remains up-to-date and a statement from the BTA Executive Committee supporting the existing guidelines was published in May 2015 in <em>Clinical Endocrinology</em> and endorsed by the Association for Clinical Biochemistry and Laboratory Medicine, the BTF, the RCP and the SOE. The full statement is attached and available online at:</p><br /><p><a href="http://onlinelibrary.wiley.com/doi/10.1111/cen.12824/full" target="_blank">http://onlinelibrary.wiley.com/doi/10.1111/cen.12824/full</a></p><br /><p>Regarding international guidance and harmonisation on approaches to testing, the existing United Kingdom guidelines have now been supported by new guidance published in the United States of America which draws on the latest research and available evidence on the management of the condition. The USA guidance also includes a section on the ethics of prescribing thyroid hormone combination therapies when the potential long-term harmful effects are not known.</p> answering member printed Lord Prior of Brampton attachment 1 file name Okosieme_et_al-2015-Clinical_Endocrinology.pdf title Clinical Endocrinology paper 2 file name the-diagnosis-and-management-of-primary-hypothyroidism-revised-statement-14-june-2011_2.pdf title Royal College of Physicians guidance 3 file name TFT_guideline_final_version_July_2006.pdf title UK Guidelines Thyroid Function Tests grouped question UIN HL2639 HL2640 HL2641 question first answered 27/10/2015 17:53:43 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	457 label Biography information for Lord Pendry

225642

	registered interest
	date	06/03/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many NICE technology appraisals were carried out in respect of (a) infectious disease, (b) cancers and tumours, (c) disorders of the blood, (d) endocrine, nutritional and metabolic problems, (e) mental health disorders, (f) neurological, (g) cardiovascular disease, (h) musculoskeletal disorders and (i) other conditions in each of the last five years.
	tabling member constituency	Denton and Reddish
	tabling member printed	Andrew Gwynne
	uin	226576
	answer	answer is ministerial correction date of answer 16/03/2015 answer text <p>The number of National Institute for Health and Care Excellence technology appraisals undertaken in respect of each disease category specified, for the last six financial years is shown in the attached table.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/03/2015 17:17:02 answering member 4020 label Biography information for George Freeman attachment 1 file name technology appraisals table.docx title NICE technology appraisals per disease catagory
	tabling member	1506 label Biography information for Andrew Gwynne